15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and...
15:26 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Taiwan Liposome planning NASDAQ listing

Drug delivery company Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million on Feb. 17 through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney...
16:41 , Feb 20, 2018 |  BC Extra  |  Financial News

Taiwan Liposome planning NASDAQ listing

Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw. The company...
19:40 , Jan 26, 2018 |  BC Week In Review  |  Company News

Taiwan Liposome forms JV with Jixi in China

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market Taiwan Liposome's drugs more efficiently in China. Jixi will invest $20 million to purchase a partial...
00:19 , Jan 23, 2018 |  BC Extra  |  Company News

Taiwan Liposome forms marketing JV with Jixi

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market its drugs more efficiently in China. Jixi will invest $20 million to purchase a partial stake...
04:54 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported data from three evaluable patients with chronic refractory mucocutaneous candidiasis in a Phase IIa trial showing that oral MAT2203 (CAmB) met the primary endpoint of reducing clinical symptoms. To...
00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
17:55 , Aug 24, 2017 |  BC Innovations  |  Translation in Brief

The skinny on leishmaniasis

University of York scientists have shown skin, not just blood, is a major route by which...
17:02 , Aug 24, 2017 |  BC Innovations  |  Translation in Brief

Spit it out

The identification of ERK-5 as a brake on the process of macrophage vomocytosis not only provides new mechanistic insight into the poorly understood phenomenon but could lead to a strategy for preventing dissemination of fungal...
23:16 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy...